/S.Law/figure3a.jpg)
Shares of biotech Intec Pharma Ltd. NTEC plunged 80% in premarket trade Monday after the company said its late-stage trial of a drug meant to treat symptoms of advanced Parkinson's disease did not result in meaningful improvement when compared with standard therapy.
How did Intec Pharma’s stock split work?
How did Intec Pharma's stock split work? Intec Pharma's stock reverse split on the morning of Tuesday, July 27th 2021. The 1-4 reverse split was announced on Tuesday, July 27th 2021. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 27th 2021.
Will Intec Pharma's (IPA) earnings drop in the coming year?
Only 22.37% of the stock of Intec Pharma is held by institutions. Earnings for Intec Pharma are expected to decrease in the coming year, from $11.96 to ($9.80) per share. The P/E ratio of Intec Pharma is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Who owns Intec Pharma (IPH)?
Intec Pharma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Migdal Insurance & Financial Holdings Ltd. (2.22%), Harel Insurance Investments & Financial Services Ltd.
What are analysts'price targets for Intec pharma's stock?
5 equities research analysts have issued twelve-month price objectives for Intec Pharma's stock. Their forecasts range from $8.50 to $16.00. On average, they expect Intec Pharma's share price to reach $13.30 in the next year.
Is Intec a good stock to buy?
Intec Pharma Ltd. (NTEC) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.
What happened to NTEC?
Following the reverse share split and Domestication Merger, Intec US will begin trading on the Nasdaq Capital Market instead of Intec Israel at the commencement of trading on July 27, 2021 under Intec Israel's existing symbol "NTEC" but with a new CUSIP number (45828B 100).
Is NTEC a buy?
In short, this is how much a company is worth....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy24.97%2Buy18.45%3Hold10.03%4Sell5.70%2 more rows
What does Intec Pharma do?
Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology.
How were Intec Pharma's earnings last quarter?
Intec Pharma Ltd (NASDAQ:NTEC) posted its earnings results on Monday, May, 17th. The biotechnology company reported ($3.84) EPS for the quarter, mi...
When did Intec Pharma's stock split? How did Intec Pharma's stock split work?
Intec Pharma shares reverse split before market open on Tuesday, July 27th 2021. The 1-4 reverse split was announced on Tuesday, July 27th 2021. Th...
Who are Intec Pharma's key executives?
Intec Pharma's management team includes the following people: Jeffrey A. Meckler , Vice Chairman & Chief Executive Officer Nir Sassi , President...
Who are some of Intec Pharma's key competitors?
Some companies that are related to Intec Pharma include Chemomab Therapeutics (CMMB) , Synthetic Biologics (SYN) , Vincerx (VINC) , Gain Therap...
What other stocks do shareholders of Intec Pharma own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Intec Pharma investors own include SCYNEXIS (SCYX) , Inov...
When did Intec Pharma IPO?
(NTEC) raised $30 million in an initial public offering (IPO) on Tuesday, August 4th 2015. The company issued 5,000,000 shares at $6.00 per share....
What is Intec Pharma's stock symbol?
Intec Pharma trades on the NASDAQ under the ticker symbol "NTEC."
How much money does Intec Pharma make?
Intec Pharma has a market capitalization of $0.00. The biotechnology company earns $-14.13 million in net income (profit) each year or ($16.32) on...
How many employees does Intec Pharma have?
Intec Pharma employs 40 workers across the globe.
How much does Intec Pharma make?
Intec Pharma has a market capitalization of $12.07 million. The biotechnology company earns $-14,130,000.00 in net income (profit) each year or ($4.08) on an earnings per share basis.
When is the 1-20 reverse split?
The 1-20 reverse split was announced on Thursday, October 29th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 29th 2020. An investor that had 100 shares of Intec Pharma stock prior to the reverse split would have 5 shares after the split.
Filing of NTEC 2020 Annual Report
On March 16, 2021, Intec Pharma Ltd filed its annual report on Form 10-K for the year ended December 31, 2020, with the U.S. Securities and Exchange Commission.
NTEC facing a legal fight over its merger with Decoy Biosystems
Intec Pharma Ltd is facing legal investigations about its merger with Decoy Biosystems.
Background of NTEC Stock Merger Agreement with Decoy Biosystems
On March 15, 2021, NTEC stock entered into a definitive agreement with Decoy Biosystems, Inc.
NTEC Stock Research collaboration with GW Pharma
On December 9, 2020, Intec Pharma Ltd entered into a feasibility agreement with GW Research Limited (GW), London, the U.K. to explore using the Accordion Pill platform for the undisclosed research program.
Conclusion
Intec Pharma Ltd facing some legal issues but we think that the merger will go ahead and at the moment we had no reason behind its exceptional performance on Wednesday.
What is Intec Pharma?
Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company's Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The Company's product pipeline includes two product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, which is in late-stage Phase 3 development for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients, and AP-cannabinoids, an Accordion Pill to deliver either or both of the primary cannabinoids contained in Cannabis sativa, cannabidiol (CBD) and tetrahydrocannabinol (THC) for various pain indications. In addition, the Company has a research collaboration with Merck & Co.
When will Intec reverse share split?
(NASDAQ: NTEC) ("Intec" or "the Company") today announces a 1-for-20 reverse share split of its outstanding ordinary shares. The reverse share split is scheduled to become effective after trading closes on October 29, 2020, and the Company's ordinary shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market at the commencement of trading on October 30, 2020 under the Company's existing symbol "NTEC." The Company's ordinary shares have been assigned a new CUSIP number of M53644148 in connection with the reverse share split. As previously disclosed, at the Company's Annual Meeting of Shareholders held on July 15, 2020, the Company's shareholders approved a proposal to amend the Company's Articles of Association to effect a reverse share split of the Company's ordinary shares at a ratio with the range from 1-for-5 to 1-for-25, to be effective at the ratio and on a date to be determined by the Company's board of directors in its sole discretion.
